The FDA has granted a controversial accelerated approval to Biogen’s anti-amyloid antibody aducanumab. Despite a lack of evidence that the therapy improves cognitive outcomes, the FDA approved the antibody based on its ability to lower the level of amyloid plaques in the brain.

Para acessar a publicação na íntegra clique aqui

Click here to original publication.